Promising drug targets Hard-to-Treat breast cancer in Early-Stage trial
NCT ID NCT07299409
First seen Jan 04, 2026 · Last updated May 22, 2026 · Updated 22 times
Summary
This study tests whether the drug Sacituzumab govitecan can slow down advanced triple-negative breast cancer when used as the first treatment. About 24 adults who have not had prior treatment for advanced disease will receive the drug on days 1 and 8 of each 21-day cycle. Researchers will also check if the drug works better in patients with a specific genetic feature called HRD compared to those without it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BC Cancer - Vancouver Center
Vancouver, British Columbia, V5Z 4E6, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.